Claritas Pharmaceuticals Inc. buy melinda
Start price
22.06.17
/
50%
€2.16
Target price
16.11.17
€4.04
Performance (%)
-16.54%
End price
16.11.17
€1.80
Summary
This prediction ended on 16.11.17 with a price of €1.80. The prediction for Claritas Pharmaceuticals Inc. disappointed with a performance of -16.54%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Claritas Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 4,64 % | 7,49 % | 6,99 % | 53,73 % |
| iShares Nasdaq 100 | 4,47 % | 16,80 % | 40,28 % | 104,33 % |
| iShares Nikkei 225® | 7,67 % | 16,86 % | 47,87 % | 73,79 % |
| iShares S&P 500 | 2,47 % | 9,90 % | 28,43 % | 72,58 % |
Comments by melinda for this prediction
In the thread Claritas Pharmaceuticals Inc. diskutieren
zu folgen
22. Juni (Reuters) - Kalytera Therapeutics Inc. :: Kalytera Therapeutics Inc. - Robert Farrell, JD, Präsident und CFO von Kalytera, wird die Rolle des Interim Chief Executive Officer übernehmen. Kalytera Therapeutics - erwartet für Patienten in einer klinischen Phase-2-Studie zur Beurteilung cbd beginnen Einschreibung ...
(Vom Mitglied beendet)
Stopped prediction by melinda for Claritas Pharmaceuticals Inc.
Claritas Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.16
22.06.17
22.06.17
€4.04
16.11.17
16.11.17
-16.54%
16.11.17
16.11.17
